This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Norman Swan, MD

JAMA. 1999;282:119-120.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Sydney—What is probably the most comprehensive review of Australian medical research ever carried out achieved one of its prime aims almost before it produced its final report. In its May budget, the federal government committed itself to almost doubling national medical research funding over the next 6 years—a measure that was a key recommendation of the review.

Although low by US and Organization for Economic Cooperation and Development standards, the funding increase from A$165 million at present to A$350 million (US $231 million) by 2005 is a welcome shot in the arm for Australia's medical research community.

Minister for Health Michael Wooldridge, MD, commissioned the Health and Medical Research Strategic Review amidst criticism that Australia was falling behind in genomic and biotechnological research and missing commercial opportunities. For example, it still galls many Australian researchers to have seen the US pharmaceutical company Amgen grow into a . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?